Sparsentan shows superior proteinuria reduction in pediatric FSGS patients, setting the stage for potential FDA approval.
Michelle Rheault, MD
Advertisement
Michelle Rheault, MD, is a pediatric nephrologist and professor of Pediatrics at the University of Minnesota.
Articles by Michelle Rheault, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5